Floatz logo

8 assets in Laryngeal Squamous Cell Carcinoma

Therapeutic assets addressing Laryngeal Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Laryngeal Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2B (57)
Abiraterone
Laryngeal Squamous Cell Carcinoma
MacroGenicsP2CCC (53)
Cabozantinib
Laryngeal Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Enzalutamide
Laryngeal Squamous Cell Carcinoma
MacroGenicsP2CCC (53)
Nivolumab
Laryngeal Squamous Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Autologous Rapamycin-Resistant Th1/Tc1 Cells Rapa-201
Laryngeal Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2CCC (48)
Pembrolizumab
Laryngeal Squamous Cell Carcinoma
Rapa Therapeutics LLCP1/2CCC (48)
Vobramitamab Duocarmazine
Laryngeal Squamous Cell Carcinoma
MacroGenicsP2C (36)